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ABSTRACT 
Introduction: Benzodiazepines are a large group of drugs used as hypnotics, 
anxiolytics, and tranquillisers, anti convulsants, pre-medication and for intravenous 
sedation. Extended use of benzodiazepines may lead to dependence and misuse. Use 
of benzodiazepines, for anxiety disorder and insomnia, is therefore just recommended 
for short-term use. Current European prescribing guidelines for usage of 
benzodiazepines for general anxiety is 4 weeks and 1-2 weeks for acute insomnia. 
Despite prescribing recommendations long-term use is widespread in medical 
practice, especially among elderly. For many years now concerns have been 
expressed over the inappropriate use of benzodiazepines in Ireland.  
Aim: The objective of this study was to determine the feasibility of exploiting 
government General Medical Services (GMS) data to provide periodic drug utilisation 
reports, and assess benzodiazepine and related drug usage in the North Eastern Health 
Board (NEHB) region during the period January 2001 to June 2003. 
Method: Prescription data over the GMS population, NEHB, from the GMS 
Payments Boards data records was interrogated by using the database program 
Filemaker pro 5, and the database analysis program SPSS11.  
Results: The results shows that the prescribing of benzodiazepines and related drugs 
gradually increased during the study period and was mainly due to an increasing for 
the benzodiazepine-related drugs zolpidem and zopiclone. The total average number 
of Defined Daily Doses (DDDs) per prescription items for all included drugs was for 
the period for 22 days supply. All the hypnotics had average number of DDDs per 
prescription higher than the recommend, for 14 days supply. As an example, 
Flunitrazepam, which is classified as a Schedule 3 controlled drug was on average 
prescribed for 33 days supply. In 2002 48.9% of the users had prescriptions in 3 or 
more consecutive months, 30.3% received prescriptions in ≥ 6 consecutive months 
and 9.7% had prescriptions in every month during 2002.  
Conclusion: Although this study has several limitations the results show that the 
prescribing of benzodiazepines and related drugs in the GMS population, NEHB 
during January 2001 to June 2003 are high and that many patients seems to be long-
term users, which is in conflict with best clinical practice.  
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1. INTRODUCTION
 
Benzodiazepines are a large group of drugs used as anxiolytics, hypnotics, 
tranquilisers, anticonvulsants, and as intravenous sedatives and for premedication in 
surgical procedures [4]. They were introduced during the early 1960s as a safer and 
less toxic alternative to barbiturates. Benzodiazepines are among the most commonly 
prescribed medications today because of their effectiveness in relieving anxiety and 
insomnia [3,4,5].   
 
In 1980´s it became clear that extended use of benzodiazepines may lead to 
dependence, misuse and withdraw reactions [3,5]. Therefore, use of benzodiazepines 
for anxiety disorder and insomnia is recommended for short-term use[21,22]. Current 
European prescribing guidelines for benzodiazepines indicated for acute insomnia is 
for 1-2 weeks and 4-weeks for general anxiety. Symptom of dependence are 
characterised by anxiety, dysphoria, perceptual changes, headaches, muscle spasms 
and sleep disturbance. Other less common symptoms include seizures and episodes of 
confusion [3,4,5,16]. Abrupt withdrawal after long-term use can induce acute anxiety, 
psychosis and convulsions. Short-acting benzodiazepines cause more abrupt 
withdrawal effects than long-acting [4,22]. Long-acting agents are more likely to 
affect performance and co-ordination the following day. 
 
Studies have suggested that up to 40% of the people who use benzodiazepines for 3 
month or longer will develop dependence, but dependence can occur even with 
shorter periods of 3-6 weeks. Therefore, the duration of treatment is an important 
factor in preventing dependence [5]. Despite the existence of benzodiazepine 
prescribing recommendations for some years and the widespread acceptance that 
prolonged benzodiazepine usage can cause dependence, long-term prescribing is 
common in medical practice.  Long-term use of benzodiazepines for the treatment of 
anxiety and insomnia has therefore become a major cause for concern.  [3, 16, 21, 22]. 
For example in the Netherlands in 1998 there were 1.9 million benzodiazepine users, 
a third used benzodiazepines chronically (defined in that study as at least 90 days[7]). 
The number of chronic users in the Netherlands was estimated to have been 
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increasing by 50,000 each year, and steps were been taken to decrease the use of 
benzodiazepines by employing restricted prescribing rules. Despite the prescribing 
restrictions, the number of prescriptions increased each year by 1.7% from 1993 to 
1998 [7]. Other studies had reported that the benzodiazepine consumption is 
increasing in Spain and Italy, while the UK, Germany and the USA have decreased 
their total benzodiazepine usage [2, 5, 22].  
 
2. BACKGROUND 
The first benzodiazepine, chlordiazepoxide was produced by chance in 1961 after 
combining a heterocyclic 6-membered ring with methylamine [13]. Soon after that, 
diazepam was introduced onto the market. Today there are about 20 different 
benzodiazepines available for clinical use around the world [4]. All the 
benzodiazepines share the same 7-membered ring and differ by their substituent 
groups [19]. 
 
Benzodiazepine dependence and withdrawal reactions became apparent in the 1980’s 
[3,5]. The risk of developing benzodiazepine dependence increases with the dose and 
the duration of treatment, the severity of symptoms, the nature of the illness, the 
expectation of beneficial effect and the intensity of stress factors. The risk is highest 
among patients with a history of addiction, chronic physical illness, personality 
disorders and chronic sleep disorders [23]. Benzodiazepine abuse has been a growing 
problem since the last decade [23]. Exceeding the prescribed dosage and obtaining 
prescriptions from several different doctors is common, especially among anxious 
patients with a history of alcohol misuse and among drug abusers [23]. 
  
2.1 Indications, Definitions and Clinical use 
Benzodiazepines have a wide range of usage. The most common indications are 
anxiety, insomnia, panic, epilepsy, muscle spasms and pre-surgical stress [4,13,23].   
 
Insomnia and anxiety are the most frequently seen symptoms in general practice [23]. 
Insomnia is characterised by difficulties with falling asleep or staying asleep. 
Insomnia is twice as common in women than in men, and increases with age (30-40% 
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of people over 65 years are dissatisfied with their sleep)[23]. Anxiety is a normal 
response to stress, and refers to a feeling of fear or apprehension, together with 
symptoms of increased sympathetic activity. There are several different types of 
anxiety. The most common include panic disorder, agoraphobia, other phobias and 
generalized anxiety. Anxiety disorders are also twice as common in females than 
male. The onset of most anxiety disorder is in young adulthood, but most cases of 
generalized anxiety and agoraphobia-panic occurs in the 50-64 year age group [23]. 
 
All benzodiazepines have principally the same pharmacological effects - hypnotic, 
anxiolytic, and anticonvulsant, though they differ in their selectivity and in their 
duration of action. Most benzodiazepines are well absorbed and rapidly penetrated 
into the brain due to their high lipid solubility. Hypnotic effects are seen within half-
an-hour, and anxiolytic effects within an hour after oral administration. Some of the 
benzodiazepines indicated for the treatment of muscle spasm and epilepsy can be 
administered intravenously or rectally for a more rapid effect [13,19, 23]. 
Benzodiazepines bind strongly to plasma protein, but because of their high lipid 
solubility they can accumulate in body fat. Their elimination half-lives vary from 6 to 
100 hours. Benzodiazepines are all inactivated by hepatic metabolism via oxidation or 
conjugation, and are excreted as glucuronide conjugates in the urine. Oxidative 
metabolism of benzodiazepines is decreased in the elderly, in patients with hepatic 
impairment and in combination with some drugs including alcohol [13, 19, 23]. 
 
Benzodiazepines vary greatly in their duration of action, mainly because of their 
differences in pharmacokinetic behaviour [22]. They can be divided into short-, and 
long-acting benzodiazepines. Short-acting benzodiazepines (e.g. flurazepam) are used 
as hypnotics and longer acting ones (e.g. chlordiazepoxide and diazepam) as 
anxiolytics and tranquillizers. Some anxiolytics can also have hypnotic effects and 
they are generally divided into: 
• Anxiolytics, tranquillizer (anti-anxiety drugs) include: 
diazepam (Valium®) 
alprazolam (Alprox®, Calmax®, Gerax® and Xanax®) 
bromazepam (Lexotan®) 
_______________________________________________________________ 6
 Benzodiazepine Usage in North Eastern Health Board Region                                   Henman, Vivero and 
Gustafsson  
 ________________________________________________________________________________ 
 
                                                
chlordiazepoxide (Librium®) 
clobazam (Frisium®) 
clorazepate (Tranxene®); 
prazepam (Centrax®) 
• Hypnotics (sleep-inducing drugs) include: 
flunitrazepam (Rohypnol®) 
flurazepam (Dalmane®) 
lorazolam (Dormonoct®) 
lormetazepam (Noctamid®) 
nitrazepam (Mogadon®, Somnite®) 
temazepam (Nortem®,Tenox®) 
triazolam (Halcion®,) [4] 
 
The long-acting benzodiazepine Diazepam (Anxicalm®, Valium®) is also used for 
the treatment of muscle spasm. Diazepam (Valium®, Sobril®, Diazemuls®) is also 
used in the treatment of all forms of epilepsy. Clonazepam (Rivotril®), Clobazam 
(Frisium®) are other benzodiazepines particularly indicated for treatment of different 
forms of epilepsy, and Lorazepam (Ativan®) may also be used. Midazolam 
(Hypnovel®) is indicated for premedication. [4,6].  
 
2.2 Mechanism of Action and Dependence  
Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter, and one of the 
most common transmitter substances in the central nervous system (CNS). GABA is 
used as a transmitter in 20-50% of all the synapses in the brain by binding to specific 
binding sites on GABA receptors, which control chloride channels. When GABA 
binds to the receptor, chloride channels open, allowing chloride to flow in. This leads 
to membrane hyperpolarization and synaptic inhibition. Benzodiazepines enhance 
GABA`s effect, through increasing the affinity for its binding site. The enhancement 
increases GABA`s neuro-inhibitory effect, which leads to a decrease in the firing rate 
of several different neuron in many regions of the CNS. There are three different 
types of GABA receptors; GABAA GABAB and GABAC. The benzodiazepines 
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interact with specific binding sites on GABAA receptors. All benzodiazepines bind to 
these sites but they differ in their degrees of affinity. There are different subtypes of 
both GABAA receptors and benzodiazepine binding sites, which are expressed in 
different areas of the CNS. Depending on which area of the brain the inhibitory effect 
takes place, different pharmacological effects (hypnotic, anxiolytic, and 
anticonvulsant) occurs [13,19,23,11]. The mechanism of benzodiazepine dependence 
is due to down-regulation of the expression of the different subunits of the GABAA 
receptor complex [10]. 
Zolpidem, (Stilnoct®) is a non-benzodiazepine with an intermediate hypnotic effect, 
indicated for short-term treatment of insomnia. This imidazopyridine derivate, binds 
to one benzodiazepine receptor subtype (omega-1;benzodiazepine-1), where as 
benzodiazepines binds to three known subtypes. The half-life for Zolpidem is very 
short, around 2 hours. Therefore, hangover effects are rare but withdrawal effects and 
tolerance have been reported in patients taking high doses. Zaleplon (Sonata®) is a 
pyrazolopyramidine indicated for treatment of insomnia. This short acting hypnotic 
binds selectively to the omega-1;benzodiazepine-1 receptor. The half-life for this 
substance is around 1 hour. As with benzodiazepines tolerance may develop 
following repeated use for a few weeks. Zopiclone, (Zimoclone®, Zimovane®, 
Zileze®, Zopitan®,Zorclone®) a cyclopyrrolone, is indicated for short term treatment 
of insomnia. It binds to two of the benzodiazepine receptor subtypes and has an half-
life around 4-6 hours. Zopiclone may have the same potential for dependence and 
withdrawal effects as benzodiazepines [23,6].  
  
2.3 Prevalence, patterns of use and risk factors for use 
The role of benzodiazepines in medical practice is controversial. There are many who 
consider that benzodiazepine consumption is too high and that the risk of dependence 
and withdrawal reactions outweighs the positive effects of the drugs, others argue that 
benzodiazepines are inexpensive, safe and effective in short-term therapy [21]. The 
reason for this controversy is that benzodiazepines are often used inappropriately and 
their use has been associated with a number of adverse effects [21].   
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The prevalence of benzodiazepine use in different countries varies from 1-10% of the 
adult population [3,22]. The highest prevalence of usage has been found in females 
and elderly people [4,16,20]. An Italian study of the use of benzodiazepines in the 
general population showed that their usage occurred in 9% of the population [16]. 
Fifty six percent were chronic users receiving daily benzodiazepine for more than six-
months (their definition), and seventy percent of the long-term users were over 65 
years of age [16]. Another Italian study reported that the use of benzodiazepines has 
increased by 53% from 1984 to 1999 and showed a prevalence of use of 
approximately 10% [2].   
 
Several studies have found an association between driving impairment and 
benzodiazepine use [1, 12, 21]. A Canadian case control study on elderly drivers 
involved in crashes resulting in injury concluded that long half-life benzodiazepines, 
such as diazepam and nitrazepam were associated with an increased risk of road 
traffic accidents [1]. The study did not find the same relationship for short half-life 
benzodiazepines. A Scottish study of drivers (aged 18 and older) involved in road 
traffic accidents also found that long half-life benzodiazepines were associated with 
an increased risk of traffic accidents [12].   
 
Benzodiazepines are mainly prescribed by general practitioners [22]. A Spanish study 
(from 1996) of the general practitioner’s (GP) prescribing patterns concluded that 
while GPs were knowledgeable about the therapeutic indications for benzodiazepine 
prescribing, they were far less aware of their potential to induce dependence [5]. Sixty 
five percent of the doctors thought that the use of benzodiazepines in therapeutic 
doses was not associated with a risk of dependence, 35% believed that high doses 
were not likely to induce dependence and 78% thought that use for up to 4 weeks had 
no risk of dependence.  
 
2.4 Elderly patients  
Benzodiazepines are the most commonly prescribed psychotropic drugs among 
elderly patients [4,15]. An Irish study of an area in Dublin, from 1999, examined 
benzodiazepine use among the elderly (≥ 65years) and reported that the drugs were 
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used by 17.3% of the study population and that the use was twice as common in 
females as in men [15]. Many elderly take benzodiazepines on a long-term basis and 
have been shown to become both physiologically and psychologically dependent [21]. 
The benzodiazepines used by elderly patients are associated with several other 
adverse outcomes. The most frequently reported adverse effects includes impaired 
psychomotor performance and cognitive impairment (especially memory), daytime 
sedation, motor vehicle accidents and increased risk of falls and fractures. Many 
studies have reported that the use of benzodiazepines is independently associated with 
an increased risk of falls among elderly [8,17,18]. Some studies have shown that the 
use of short-acting benzodiazepines by elderly people is linked to a greater risk of 
falls, while others have demonstrated a relationship between long-acting 
benzodiazepines and the risk of falls among the elderly leading to hip fracture. [18]  
 
Long-acting benzodiazepines are likely to accumulate in older people, due to their 
decreasing metabolic function, which can result in an increased risk for sedative 
effects and psychomotor impairment [4, 23].  
 
2.5 Benzodiazepine Use in The Republic of Ireland 
All benzodiazepines are controlled by Misuse of Drugs Regulations in Ireland and are 
classed as Controlled Drugs. Two of the benzodiazepine drugs, flunitrazepam and 
temazepam are classed as Schedule 3 in the Misuse of Drugs Regulations, the rest are 
listed in Schedule 4 of these regulations [4]. Benzodiazepines and related drugs can 
only be prescribed on a single prescription and cannot exceed a maximum of 30 days 
supply [15].    
 
For many years now, concerns have been expressed over the inappropriate use of 
benzodiazepines in Ireland. The major medical bodies in Ireland (the Irish college of 
General Practitioners, the Royal College of Psychiatrists and the Royal College of 
Physicians) recommend that benzodiazepines should not be prescribed for more than 
2-4 weeks. However evidence remains of many long-term benzodiazepine users in 
Ireland and in June 2000 the Benzodiazepine Committee was established by Mr 
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Micheal Martin, T.D., and Minister for Health and Children [4]. The aims of the 
committee were: 
• To examine the current prescribing and usage of benzodiazepines and related 
drugs (zaleplon, zolpidem and zopiclone) 
• To consider recommendations on good prescribing and dispensing practice, 
paying particular attention to the management of drug misusers; 
• To make recommendations as appropriate [4]. 
 
At the request of the Benzodiazepine Committee, two studies examined the use of 
benzodiazepines in the Irish GMS population. Both studies used data from the 
General Medical Services (GMS) scheme records. The first study examined the use of 
benzodiazepines and related drugs (related drugs = ATC Code N05CF which 
includes: zaleplon, zolpidem and zopiclone) in the whole adult GSM population over 
the years 1995 to 2000. Results from this study indicated that the prescribing of 
benzodiazepines and related drugs are increasing and that the usage in this population 
was high. Usage of the benzodiazepine and related drugs increased gradually from 87 
Defined Daily Doses (DDDs) per 1000 of the adult (≥15 years) GMS population (for 
definition, see below) in 1995 to 116 DDDs in 2000. According to this study 11.6% 
of the adult GMS population used benzodiazepines and related drugs in 2000 [4].  
 
The other study looked at the benzodiazepine use in the GMS population, Eastern 
Regional Health Authority area (one of Ireland’s eight health authority areas) for two 
six-month periods (January to June 1999 and January to June 2000). This study 
showed that the use of benzodiazepines increased with age. The highest prevalence of 
usage was found in females and among patients in their late 60s and early 70s. Almost 
14% of the study population were prescribed benzodiazepines at least once over the 
six month period in 1999. For the same six month period in 2000, this figure has 
decreased to 9.9%, which could indicate that the prescribing was reducing slowly 
over time. The two studies were acknowledged to have had several limitations and the 
Committee concluded that further evaluations of the prescribing of benzodiazepines 
in Ireland must be carried out [4].   
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2.6 General Medical Services (GMS) scheme 
The Irish National Health Service is a combination of state supported and private 
practice service [9]. Approximately 31% (1.24 million) of the Irish population are 
eligible for General Medical Services (GMS) scheme which supplies all medicines 
without any cost to socially disadvantaged persons and their dependants, based upon a 
means test. All persons ≥70 years of age are also entitled to GMS membership. The 
GMS population received about 70% of all medications prescribed in general 
practices at a cost of 340 million Euros in 2000. Community pharmacies providing 
services for GMS patients use computer software for dispensing and processing the 
claims information to the GMS Payments Board. The Payments Board then processes 
the pharmacist’s claims and keeps a record of them. The GMS Payments Board data 
records contains information such as: claim number-, patient GMS number-, 
prescribing doctor-, pharmacy number, drug name, drug code, ATC level, 
pharmaceutical form, strength, Defined Daily Doses (DDD), price, month and year. 
The drugs are classified according to the World Health Organizations (WHO) 
Anatomical Therapeutic Chemical (ATC) classification system. The quantitative unit 
Defined Daily Doses (DDDs) is the assumed average maintenance dose per day for a 
drug used for its main indication in adults [24]. For each drug a theoretical daily dose 
(DDD) has been defined based on the recommended daily use by an adult for the 
drugs mains indication. The DDDs for the drugs are updated by the WHO 
Collaborating Centre for Drug Statistics methodology in Oslo, Norway.   
 
2.7 GMS in North Eastern Health Board (NEHB) 
The North Eastern Health Board covers the Republic of Ireland counties of Louth, 
Meath, Cavan and Monaghan (see map below) with a total population of 344.965 
persons in November 2003. In Nov 2003 30.09% (103454/344.965) of the NEHB 
population was eligible for GMS and of those 77.6% (80.503/103.787) were ≥15 
years old. For the same period there was 154 GMS Panel Agreements in NEHB (154 
General Practitioners in the area available for the GMS population).  
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The white area show the North Eastern Health Board area, Ireland. 
 
3. AIM 
 
The objective of this study was to determine the feasibility of exploiting government 
General Medical Services (GMS) data to provide periodic drug utilisation reports, and 
assess benzodiazepine and related drug usage in the North Eastern Health Board 
(NEHB) region during the period January 2001 to June 2003. 
 
4. METHOD 
 
Prescription data from the GMS Payments Boards data records were available for 
evaluation and analysis. The GMS Payments Board data records from the period of 
January 2001 to June 2003 was interrogated by using the database program Filemaker 
pro 5 and the database analysis program SPSS11 to study prescribing and usage 
patterns of benzodiazepines and related drugs;  zaleplon, zolpidem and zopiclone 
among the Republic of Ireland’s NEHB region GMS patients. The GMS population in 
the NEHB constitute approximately 30% of the total population in NEHB (for more 
details see Table 1 Population Data). The GMS Payments Board data records contain 
information such as; claim-, patient-, prescribing doctor-, pharmacy number, drug 
name, drug code, ATC level, pharmaceutical form, strength, Defined Daily Doses 
(DDD), price, month and year. The drugs were classified according to the World 
Health Organisations (WHO) Anatomical Therapeutic Chemical (ATC) classification 
system.  
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ere included since they have similar effects as 
enzodiazepines, use of them are increasing and they may cause dependence, 
iod in 2003 at the time for 
e study. All the descriptive statistics which for example included frequencies and 
ssumed average maintenance 
 were expressed in terms of the number of DDDs per 1000 of the 
dult  (≥15years), and overall GMS population in North Eastern Health Board 
In this study records with ATC codes N05BA (anxiolytics containing benzodiazepine 
derivatives), N05CD (hypnotics containing benzodiazepine derivatives), N03AE01 
(Clonazepam, antiepileptic) and N05CF (hypnotics containing benzodiazepine related 
drugs) were included and examined. The drugs with ATC code N05CF (Zaleplon, 
Zolpidem and zopiclone) w
b
withdrawal effects and abuse. 
 
The data record files were available on the database File maker pro 5 on a Macintosh 
computer and included two six months files with 2001 data (Jan-Jun) and (Jul-Dec) 
and one file for every month, for 2002 and for the first six month in 2003 (Jan-Jun). 
After collecting all the useful data from the File maker pro and creating and 
converting it into new files, the data were transferred to a PC. On the database 
analysis program SPSS 11 the files were merged together into six-month files, (Jan-
Jun: 2001, 2002 and 2003) and (Jul-Dec: 2001, 2002) and year files (2001 and 2002). 
There were no data available for the second six months per
th
cross-tabulations of the data were then made on SPSS11.   
 
As a quantitative unit Defined Daily Doses (DDDs) was used, which is the unit 
normally used in drug utilisation studies. DDDs are the a
dose per day for a drug used for its main indication in adults. The number of DDDs 
per prescription was calculated with following formula:  
Quantity/ (DDD (mg)/Strength (mg)). To estimate the proportion of the population 
treated daily with benzodiazepines, and to compare the results with other studies, the 
drug consumption
a
Region, Ireland.  
 
The literature search used the database PubMed and searches for articles with the 
keywords: benzodiazepine use, benzodiazepines AND prescription patterns, 
benzodiazepines AND elderly, benzodiazepines AND long-term use, benzodiazepines 
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AND withdrawal, benzodiazepines AND dependence were carried out. Trinity 
College library on-line (www.tcd.ie) was used to search for literature about the 
bject and the British National Formulary web-site (www.bnf.orgsu ) was used to 
mation about all the included substances.  
5. R
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ESULTS 
 
North Eastern Health Board (NEHB) Populations 
 
 
 
B MS 
.) 
Adults 
 
Patients 
ze
atients*  
iaz
epine 
* 
lt 
diaz
pine 
ts 
Time 
Period
NEH
Region 
GMS 
ts Patien
Adult G
>15 yrs(
% 
GMS
Benzodia
ine p
p
Adult 
Benzod
patients
% 
enzo
Adu
B
e
patien
2001 No 
atistics 
ailable 
5,247 
ec) 
,802 7,7 
St
Av
10
(D
81
 
7 20,114 
 
19892 98,9 
 
2001 
(Jan-June) 
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- - -  16,149 
 
 16,029 99,3 
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4,926 
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7 21,513 
 
21,273 98,9 
 
2002 
(Jan-June) 
7 1 9,2 - - -  16,52
 
16,39 9
2002 
(July-Dec) 
- - -  16,724 
 
16,600 99,3 
2003 344,965 103,787 80,503 77,6 N/A 
 
N/A 
 
 
 (Nov) (Nov)  
2
(J
003 - - -  
an-June)   
16,815 16,695 99,3 
* GMS Patients prescribed benzodiazepine or related drug (N05BA, N05CD, N05CF, N03AE01) 
Table 1. Population Data North Eastern Health Board (NEHB). 
 
The North Eastern Health Board covers the counties of Louth, Meath, Cavan and 
Monaghan with a total population of 344926 persons in December 2002 and 344965 
persons in November 2003. In 2002 and 2003 approximately 30% of the total NEHB 
population was eligible for the GMS scheme. Prior to 2002, the most recent 
population survey of the NEHB region was conducted in 1996, therefore the 
roportion of the population eligible for the General Medical Services could not be p
determined for 2001.  
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Thr
were adults (≥15 years). Of the prescribed benzodiazepines and related drugs 99% 
ere for adult persons. 
sis of the prescribing of GMS Benzodiazepine and Related Drug 
oughout the period January 2001 to July 2003 about 78% of the GMS population 
w
5.1 Analy
Usage 
 
Yearly Data 
In 2001 the use of benzodiazepines and related drugs, expressed as the total number 
of DDDs/1000 GMS Patients/Day dispensed was 80.52. In 2002 this figure had 
increased by 13.5% to 91.38% (See Chart 1 and Table 3).  
 
Yearly GMS Benzodiazepine and Related Drug Use
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Chart 1. Benzodiazepine and Related Drug Usage 2001 and 2002. 
 
 
 2001 2002 
No. of DDDs/1000 
patients/Day 
80.518 91.379 
No. of Prescription Items 140,757 160,985 
No. of Claims 115,599 143,171 
 
Table 2. Yearly Benzodiazepine and Related Drug Usage 
Six-Month Data 
The prescribing of benzodiazepines and related drugs in the GMS population NEHB 
gradually increased during the study period January 2001 to June 2003. The 
dispensed quantity, expressed in terms as the total number of DDDs/1000 GMS 
Patients/Day was for the first six-month period 2001 was 79.1. For the same period in 
_______________________________________________________________ 16
 Benzodiazepine Usage in North Eastern Health Board Region                                   Henman, Vivero and 
Gustafsson  
 ________________________________________________________________________________ 
 
                                                
 of 
DDs/1000 patients/Day was 81.9 and had increased by 12.6% to 92.2 in 2002. There 
was no data available for the second six month period of 2003 (see Table 4 and Chart 
2). The dispensed amount increased by almost 21% over the whole study period.   
 
2002 this figure increased by 14.4% to 90.51 and in 2003 by 6% to 95.6 (see Table 3 
and Chart 2). For the second six month period of 2001 the total number
D
Benzodiazepine usage in the GMS population in NEHB
Jan 2001 - June 2003
95,55892,22490,5181,91479,099
0
20
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Jan-June Jul-Dec
2001 2002 
Jan-June 
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Drug Usa uary 2001-June 2
Year 
Chart 2. Benzodiazepine and Related ge Jan 003 
 
 
1st Six-Month period of Each 
Jan-Jun 2001 2002 2003 
No. of DDDs/1000 79.099 90.510 95.558 
patients/Day 
No. of Prescription 
ems 
67,967 78,747 83,227 
It
No. of Claims 50,424 69,958 73,855 
Table 3. Jan-Jun Benzodiazep d Related Dru e 
Eac  
ine an g Usag
 
 
2nd Six-Month period of h Year
July-Dec 2001 2002 
No. of DDDs/1000 81,914 92,224 
patients/Day 
No. of Prescription Items 72,790 72,240 
No. of Claims 65,176 73,213 
Table 4. Jul-Dec Benzodiazepine and Related Drug Usage 
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5.2 Breakdown by Drug Analysis 
Yearly Data 
When comparing the total number of DDDs/1000/Day for each drug separately, all 
the typical anxiolytics and hypnotics increased in 2002 compared to 2001. The 
highest increase was seen for Alprazolam (anxiolytics), Temazepam (hypnotic), 
Zolpidem (non-benzodiazepine hypnotic) and Zopiclone (non-benzodiazepine 
hypnotic). The total number of DDDs/1000/Day fell slightly for four of the drugs; 
Zaleplon (non-benzodiazepine hypnotics), Clobazam (antiepileptic,) Midazolam 
(premedication) and clonazepam (antiepileptic). When the percentage of the total 
number of DDDs for each drug is compared, only Zolpidem and Zopiclone increased. 
Tablets and capsules were the main dose forms prescribed, which explains why the 
total number of DDDs/1000/Day was almost the same when just including these dose 
forms (See Table 5 and Chart 3). 
International Non- 
Proprietary Name 
No. of DDDs /1000 Patients/Day          (All Dosage Forms) 
 ATC code 2001 2002 
Alprazolam N05BA12 11.048 (13.72%) 12.865 (14.08%) 
Bromazepam N05BA08 3.172   (3.94%) 3.421   (3.74%) 
Chlordiazepoxide N05BA02 0.960. (1.19%) 1.039   (1.14%) 
Clobazam N05BA09 1.046   (1.30%) 1.003   (1.10%) 
Clonazepam N03AE01 0.209   (0.26%) 0.205   (0.22%) 
Clorazepate N05BA05 0.842   (1.05%) 0.908   (0.99%) 
Diazepam N05BA01 11.476 (14.25%) 12.192 (13.34%) 
Flunitrazepam N05CD03 3.782   (4.70%) 3.845   (4.20%) 
Flurazepam N05CD01 6.720   (8.34%) 7.234   (7.92%) 
Lorazepam N05BA06 1.256   (1.56%) 1.372   (1.50%) 
Lormetazepam N05CD06 4.769   (5.92%) 5.522   (6.04%) 
Midazolam N05CD08 0.045   (0.06%) 0.038   (0.04%) 
Nitrazepam N05CD02 5.191   (6.44%) 5.560   (6.08%) 
Prazepam N05BA11 0.295   (0.36%) 0.314   (0.34%) 
Temazepam N05CD07 12.801 (15.90%) 14.268 (15.60%) 
Triazolam N05CD05 2.226   (2.76%) 2.461   (2.69%) 
Zaleplon N05CF03 0.498   (0.62%) 0.463   (0.51%) 
Zolpidem N05CF02 4.529   (5.62%) 6.539   (7.16%) 
Zopiclone N05CF01 9.673 (12.01%) 12.124 (13.27%) 
Total No. of  DDDs/1000/Day 80.518 (100%) 91.374 (100%) 
Total DDDs/1000/Day (Tabs & Caps) 80.414 91.283 
Table 5. Yearly Total GMS Population Usage of Benzodiazepine and Related Drugs 
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Yearly quantity of drugs prescribed: DDDs/1000 GMS patients/Day For Each 
Drug
2001-2002 
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 Chart 3. Yearly No. of DDDs/1000 GMS patients/Day For Each Drug 
Six-Month Data 
As for the 12 month data, the dispensed quantity of the most frequently prescribed 
anxiolytics and hypnotics were greater for Jan-June 2002 compared to the same period in 
2001. The increase between the six month period in 2002 and 2003 was smaller than 
between 2001 and 2002 and was mainly due to an increase for the benzodiazepine-
related drugs Zolpidem and Zopiclone. Although there was a small increase for the 
benzodiazepine drugs Temazepam (hypnotic), Diazepam (anxiolytic, anticonvulsant), 
Alprazolam (anxiolytic), Flurazepam (hypnotic) and Lorazepam (anxiolytics, 
anticonvulsant). The number of DDDs/1000/Day was lower in 2003 compared to 2001 
and 2002 for the drugs Zaleplon (non-benzodiazepine hypnotic), Clobazam 
(antiepileptic), Flunitrazepam (hypnotic) and Midazolam (premedication). When the 
percentage of the total number of DDDs for the individual drugs was compared, only 
Zolpidem and Zopiclone showed an increase. Zolpidem constituted 5.2% of the total 
number of DDDs in 2001 and increased to 9.0% in 2003. Zopiclone increased from 
11.65% in 2001 to 14.65% in 2003. As for the 12 month data the main dose forms were 
tablets and capsules so the difference between the total numbers of DDDs/1000/Day for 
all dose forms and for just tablets and capsules was minimal (see Table 6 and Chart 4). 
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1st Six-Month period of Each Year 
(Jan-Jun) 
 
International 
Non-Proprietary Name 
No. of DDDs/1000 GMS Patients/Day 
 
 ATC code 2001 
 
2002 
 
2003 
 
Alprazolam N05BA12 10.778 (13.63%) 12.78 (14.12%) 13.207 (13.82%) 
Bromazepam N05BA08 3.170 (4.00%) 3.319 (3.67%) 3.439   (3.60%) 
Chlordiazepoxide N05BA02 0.949 (1.20%) 1.031 (1.14%) 1.089   (1.14%) 
Clobazam N05BA09 1.079 (1.36%) 1.007 (1.11%) 0.988   (1.03%) 
Clonazepam N03AE01 0.209 (0.26%) 0.225 (0.25%) 0.237   (0.25%) 
Clorazepate N05BA05 0.840 (1.06%) 0.910 (1.01%) 0.914   (0.96%) 
Diazepam  N05BA01 11.639 (14,71%) 12.099 (13.37%) 12.476 (13.05%) 
Flunitrazepam N05CD03 3.820 (4,83%) 3.879 (4.29%) 3.718   (3.89%) 
Flurazepam N05CD01 6.735 (8,51%) 7.174 (7.93%) 7.241   (7.58%) 
Lorazepam N05BA06 1.250 (1,58%) 1.346 (1.49%) 1.466   (1.53%) 
Lormetazepam N05CD06 4.562 (5,77%) 5.572 (6.16%) 5.463   (5.72%) 
Midazolam N05CD08 0.041 (0.05%) 0.042 (0.05%) 0.027   (0.03%) 
Nitrazepam N05CD02 5.218 (6.60%) 5.745 (6.35%) 5.094   (5.33%) 
Prazepam N05BA11 0.295 (0.37%) 0.325 (0.36%) 0.319   (0.33%) 
Temazepam N05CD07 12.488 (15.79%) 14.202 (15.69%) 14.356 (15.02%) 
Triazolam N05CD05 2.196 (2.78%) 2.382 (2.30%) 2.464   (2.58%) 
Zaleplon N05CF03 0.521 (0.66%) 0.470 (0.52%) 0.427   (0.45%) 
Zolpidem N05CF02 4.128 (5.22%) 5.939 (6.56%) 8.636   (9.04%) 
Zopiclone N05CF01 9.181 (11.61%) 12.058 (13.32) 13.998 (14.65%) 
Total No. of DDDs/1000/Day 
 
79.100 (100%) 90.510 (100%) 95.559 (100%) 
Total No. of  DDDs/1000/Day 
(Tabs & Caps) 
78.993 90.419 95.474 
Table 6. Total GMS Population Usage of Benzodiazepine and Related Drugs for the 1st six-month 
periods in 2001, 2002 and 2003.  
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1st Six-Month period of each year :
Quantity of drugs prescribed in DDDs/1000 GMS Patients/Day For Each Drug
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Chart 4.1st Six-Month of each year:  No. of DDDs/1000 GMS patients/Day for Each Drug 
 
2nd Six Month Period 
The trend for the period Jul-Dec was the same as for the entire year data: the 
dispensed quantity, expressed as the total number of DDDs/1000 GMS Patients/Day 
for all the included drugs and all dose forms was higher 2002 than for the same period 
in 2001. In 2001 the total number of DDDs/1000 GMS Patients/Day was 81.9 and 
increased by 12.6% to 92.2 in 2002. The quantities prescribed for all the typical 
anxiolytics and hypnotics were greater for the period in 2002 compared to 2001. The 
greatest increase was seen for the drugs Alprazolam (anxiolytic), Temazepam 
(hypnotic), Zolpidem (non-benzodiazepine hypnotic) and Zopiclone (non-
benzodiazepine hypnotic) (See Table 7 and Chart 5).The numbers were also higher 
for the 2nd six-month period compared to the 1st six-month period of 2001 and 2002.  
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2nd Six-Month period of each year 
(Jul-Dec) 
International Non- 
Proprietary Name 
No. of DDDs/1000 GMS Patients/Day 
 ATC code 2001 
(July-Dec) 
2002 
(July-Dec) 
Alprazolam N05BA12 11.313 (13,81%) 12.947 (14,04%) 
Bromazepam N05BA08 3.174 (3,87%) 3.521 (3,82%) 
Chlordiazepoxide N05BA02 0.970 (1,18%) 1.047 (1,14%) 
Clobazam N05BA09 1.014 (1,24%) 0.998 (1,08%) 
Clonazepam N03AE01 0.208 (0,25%) 0.185 (0,2%) 
Clorazepate N05BA05 0.845 (1,03%) 0.907 (0,98%) 
Diazepam N05BA01 11.316 (13,81%) 12.283 (13,32%) 
Flunitrazepam N05CD03 3.723 (4,55%) 3.812 (4,13%) 
Flurazepam N05CD01 6.705 (8,19%) 7.292 (7,91%) 
Lorazepam N05BA06 1.262 (1,54%) 1.397 (1,51%) 
Lormetazepam N05CD06 4.972 (6,07%) 5.473 (5,93%) 
Midazolam N05CD08 0.049 (0,06%) 0.034 (0,037%) 
Nitrazepam N05CD02 5.164 (6,3%) 5.378 (5,83%) 
Prazepam N05BA11 0.295 (0,36%) 0.304 (0,33%) 
Temazepam N05CD07 13108 (16,0%) 14.333 (15,54%) 
Triazolam N05CD05 2.243 (2,74%) 2.539 (2,75%) 
Zaleplon N05CF03 0.472 (0,58%) 0.456 (0,49%) 
Zolpidem N05CF02 4.923 (6,01%) 7.130 (7,73%) 
Zopiclone N05CF01 10.157 (12,40%) 12.190 (13,22%) 
Total No of DDDs/1000/Day 81.914 (100%) 92.224 (100%) 
Total No. of  DDDs/1000/Day 
(Tabs & Caps) 
81.811 92.132 
Table 7. Total GMS Population Usage of Benzodiazepine and Related Drugs for the 2nd 
six-month period in 2001 and 2002. 
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2nd Six-Month period of each year:  Quantity of drugs prescribed in DDDs/1000 
GMS Patients/Day For Each Drug
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Chart 5. 2nd Six-Month period of ach year:  Quantity prescribed in DDDs/1000 GMS Patients/Day 
for Each Drug 
 
 
 
5.3 Adult GMS Population Benzodiazepine and Related Drug Usage 
 
Yearly Data 
The use of benzodiazepines or related drugs in the adult GMS population NEHB, in 
terms as number of DDDs/1000 GMS Adults/Day dispensed was 103.48 for the year 
2001 and increased by 13.6% to 117.56 during 2002. The prescribed quantities for 
both the hypnotics and anxiolytics were higher in 2002 compared to 2001.  
The highest increasing is seen for Alprazolam (anxiolytic), Temazepam (hypnotic), 
Zolpidem (non-benzodiazepine hypnotics) and Zopiclone (non-benzodiazepine 
hypnotics). The total number of DDDs/1000/Day prescribed decreased for Zaleplon 
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(non-benzodiazepine hypnotics), Clobazam (antiepileptic), Midazolam 
(premedication) and Clonazepam (antiepileptic) (see Table 8 and Chart 6, 7).      
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Chart 6.Yearly No. of DDDs/1000 GMS Adults/Day, 2001 and 2002. 
 
 
 
Prescribed quantity - DDD/1000 GMS Adults/Day 
 
International Non-
Proprietary Name 
(All dosage forms) 
ATC code 2001 
(n=81802) 
2002 
(n=81061) 
Diazepam N05BA01 14.731 (14.24%) 15.662 (13.32%) 
Chlordiazepoxide N05BA02 1.234 (1.19%) 1.338 (1.14%) 
Clorazepate N05BA05 0.641 (0.61%) 1.169 (0.99%) 
Lorazepam N05BA06 1.616 (1.56%) 1.765 (1.5%) 
Bromazepam N05BA08 4.078 (3.94%) 4.403 (3.75%) 
Clobazam N05BA09 1.341 (1.30%) 1.288 (1.10%) 
Prazepam N05BA11 0.379 (0.37%) 0.405 (0.34%) 
Alprazolam N05BA12 14.184 (13.71%) 16.528 (14.06%) 
Flurazepam N05CD01 8.644 (8.35%) 9.316 (7.92%) 
Nitrazepam N05CD02 6.678 (6.45%) 7.164  (6.09%) 
Flunitrazepam N05CD03 4.850 (4.69%) 4.955 (4.21%) 
Triazolam N05CD05 2.855 (2.76%) 3.167 (2.7%) 
Lormetazepam N05CD06 6.133 (5.93%) 7.113 (6.05%) 
Temazepam N05CD07 16.462 (15.91%) 18.372 (15.63%) 
Midazolam N05CD08 0.057 (0.06%) 0.048 (0.04%) 
Zopiclone N05CF01 12.431 (12.01%) 15.606 (13.28%) 
Zolpidem N05CF02 5.817 (5.62%) 8.400 (7.15%) 
Zaleplon N05CF03 0.638 (0.62%) 0.595 (0.51%) 
Clonazepam N03AE01 0.268 (0.26%) 0.264 (0.22%) 
Total No of DDDs/1000/Day 103.477 (100%) 117.559 (100%) 
Total No. of  DDDs/1000/Day 
(Tabs & Caps) 
103.349 117.447 
Table 8. Yearly Adult GMS Population Usage of Benzodiazepine and Related Drugs 
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Yearly prescribed quantity - DDDs/1000 GMS Adults/Day
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 Chart 7.Yearly prescribed quantity: DDDs/1000 GMS Adults/Day for Each Drug 
Six-Month Data – 1st Six-Month Period 
The overall prescribing of benzodiazepines and related drugs gradually increased 
during the 1st six month periods of 2002 and of 2003 compared to 2001. The total 
number of DDDs/1000 GMS Adults/Day for all the included drugs increased from 
101.6 in the 1st six month period of 2001 by 14.7% to 116.5 in Jan-June 2002 and by 
5.6% to 123.0 for the same period in 2003. The increase was greater between 2001 
and 2002 than between 2002 and 2003. All of the most frequently prescribed 
anxiolytics and hypnotics increased in usage during Jan-Jun in 2001 compared to the 
same period in 2002. But the increase between the six month period in 2002 and 2003 
was mainly due to an increase in the benzodiazepine-related drugs Zolpidem and 
Zopiclone. If the figures for the total number of DDDs per drug are compared, 
Zolpidem and Zopiclone were the only drugs that are increased. Zolpidem constituted 
5.2% of the total number of DDDs in 2001 and increased to 9.0% in 2003. Zopiclone 
increased from 11.60% in 2001 to 14.7% in 2003. 
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1st Six-Month period of each year
Quantity of DDDs/1000 GMS Adults/Day
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Chart 8.  1st Six-Month period of each year prescribed quantity: DDDs/1000 GMS 
Adults/Day during 2001, 2002 and 2003. 
 
 
  No. of DDDs/1000 GMS Adults/Day 
International Non-
Proprietary Name 
(All dosage forms) 
ATC code 2001 
Jan-Jun 
2002 
Jan-Jun 
2003 
Jan-Jun 
Diazepam N05BA01 14.938 (14.70%) 15.554 (13.36%) 16.040 (13.04%) 
Chlordiazepoxide N05BA02 1.221 (1.20%) 1.328 (1.14%) 1.404 (1.14%) 
Clorazepate N05BA05 1.081 (1.06%) 1.170 (1.00%) 1.178 (0.96%) 
Lorazepam N05BA06 1.608 (1.58%) 1.732 (1.49%) 1.890 (1.54%) 
Bromazepam N05BA08 4.075 (4.00%) 4.273 (3.67%) 4.431 (3.60%) 
Clobazam N05BA09 1.384 (1.36%) 1.290 (1.11%) 1.273 (1.03%) 
Prazepam N05BA11 0.379 (0.37%) 0.419 (0.36%) 0.410 (0.33%) 
Alprazolam N05BA12 13.831 (13.61%) 16.426 (14.10%) 16.981 (13.8%) 
Flurazepam N05CD01 8.661 (8.52%) 9.238 (7.93%) 9.329 (7.58%) 
Nitrazepam N05CD02 6.712 (6.60%) 7.401 (6.35%) 6.557 (5.33%) 
Flunitrazepam N05CD03 4.911 (4.83%) 4.998 (4.29%) 4.793 (3.90%) 
Triazolam N05CD05 2.823 (2.78%) 3.067 (2.63%) 3.176 (2.58%) 
Lormetazepam N05CD06 5.865 (5.77%) 7.176 (6.16%) 7.040 (5.72%) 
Temazepam N05CD07 16.053 (15.80%) 18.288 (15.70%) 18.498 (15.03%) 
Midazolam N05CD08 0.053 (0.05%) 0.054 (0.046%) 0.035 (0.03%) 
Zopiclone N05CF01 11.793 (11.60%) 15.529 (13.33%) 18.025 (14.65%) 
Zolpidem N05CF02 5.299 (5.21%) 7.627 (6.55%) 11.116 (9.03%) 
Zaleplon N05CF03 0.670 (0.66%) 0.603 (0.52%) 0.551 (0.45%) 
Clonazepam N03AE01 0.269 (0.26%) 0.290 (0.25%) 0.305 (0.24%) 
Total No. of DDDs/1000/Day 101.626 (100%) 116.463 (100%) 123.033 (100%) 
Total No. of  DDDs/1000/Day 
(Tabs & Caps) 
101.496 116.352 122.931 
Table 10. 1st Six-Month period of each year: quantity of DDDs/1000 GMS Adults/Day 
prescribed for each Drug during 2001, 2002 and 2003. 
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 Chart 9. 1st Six-Month period of each year: Quantity prescribed in DDDs/1000 GMS Adults/Day 
for each Drug 
 
2nd Six-Month Period 
 
The total number of DDDs/1000 GMS Adults/Day for all the included drugs and all 
dose forms were higher for the period Jul-Dec 2002 than for the same period in 2001, 
(105.3 compared to 118.6). The numbers were also higher for the 2nd six-month 
periods compared to the 1st six-month periods of 2001 and 2002. The number of 
DDDs/1000/Day of the most frequently prescribed anxiolytics and hypnotics were 
greater the period in 2002 compared to 2001. (see Table 10 and Chart 10,11 ). The 
greatest increase was seen for the drugs Alprazolam (anxiolytic), Temazepam 
(hypnotic), Zolpidem (non-benzodiazepine hypnotic) and Zopiclone (non-
benzodiazepine hypnotic). 
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Chart 10. 2nd Six-Month period of each year: Quantity of DDDs/1000 GMS Adults/Day 
prescribed for each Drug 
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 Chart 11. 2nd Six-Month period of each year:  Quantity of DDDs/1000 GMS Adults/Day prescribed 
for each Drug 
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  No. of DDDs/1000 GMS Adults/Day 
International Non-
Proprietary Name 
(All dosage forms) 
ATC code 2001 
Jul-Dec 
2002 
Jul-Dec  
Diazepam N05BA01 14.527 (13.8%) 15.768 (13.29%) 
Chlordiazepoxide N05BA02 1.247 (1.18%) 1.349 (1.14%) 
Clorazepate N05BA05 1.084 (1.03%) 1.168 (0.98%) 
Lorazepam N05BA06 1.624 (1.54%) 1.798 (1.52%) 
Bromazepam N05BA08 4.081 (3.88%) 4.531 (3.82%) 
Clobazam N05BA09 1.298 (1.23%) 1.286 (1.08%) 
Prazepam N05BA11 0.379 (0.36%) 0.391 (0.33%) 
Alprazolam N05BA12 14.530 (13.8%) 16.629 (14.02%) 
Flurazepam N05CD01 8.627 (8.19%) 9.394 (7.92%) 
Nitrazepam N05CD02 6.644 (6.31%) 6.929 (5.84%) 
Flunitrazepam N05CD03 4.789 (4.55%) 4.912 (4.14%) 
Triazolam N05CD05 2.886 (2.74%) 3.266 (2.75%) 
Lormetazepam N05CD06 6.397 (6.08%) 7.052 (5.94%) 
Temazepam N05CD07 16.863 (16.01%) 18.454 (15.56%) 
Midazolam N05CD08 0.061 (0.06%) 0.043 (0.04%) 
Zopiclone N05CF01 13.058 (12.40%) 15.681 (13.22%) 
Zolpidem N05CF02 6.326 (6.00%) 9.161 (7.72%) 
Zaleplon N05CF03 0.606 (0.57%) 0.587 (0.50%) 
Clonazepam N03AE01 0.268 (0.25%) 0.239 (0.20%) 
Total No. of DDDs/1000/Day 105.297 (100%) 118.636 (100%) 
Total No. of  DDDs/1000/Day 
(Tabs & Caps) 
105.170 118.525 
Table 10.  2nd six-month period of each Year: Quantity of DDDs/1000 GMS Adults/Day 
prescribed for each Drug 
 
5.4 Prescription Item Analysis 
Yearly Data 
 
Year Total 
No. of 
Claims 
Total No. of 
Prescribed 
Items 
Total No. of 
DDDs 
Ave. 
No. of 
DDDs/ 
Item 
Ave. No. of 
Items /GMS 
Patient 
Ave. No. of 
Items 
/Benzodiazepi
ne patient* 
Ave. No. 
Claims/ 
Benzodiazepi
ne patient* 
2001 115,599 140,757 3,093,120.71 21.97 
(3093120.
71/14075
7) 
1.34 
(140757/105247) 
7.00 
(140757/20114) 
5.75 
(115599/201114) 
2002 143,171 160,985 3,483,402.96 21.64 
(3483402.
96/16098
5) 
1.54 
(160985/104445) 
7.48 
(160985/21513) 
6.66 
(143171/21513) 
*Benzo population includes all patients prescribed benzodiazepine and related drugs (ATC code: N05BA, N05CD, 
N05CF and N03AE01) in the NEHB GMS population.  
 
Table 11. Yearly prescribing frequency and average number of DDDs dispensed per 
prescription item for benzodiazepine and related drugs 
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In 2001, 19.1% (20114/105247) of the total GMS population in the NEHB were 
prescribed a benzodiazepine derivate or related drug at least once. In 2002 this figure 
increased to 20.6% (21513/104445), (for population data see Chart1). On average, each 
GMS patient received 1.34 and 1.54 prescription items per year for 2001 and 2002 
respectively. Taking only those GMS patients prescribed a benzodiazepine or related 
drug (benzodiazepine patient) into account, the average number of prescription items 
per patient was 7 and 7.5 per year respectively. The average number of claims per 
benzodiazepine patient increased from 5.75 in 2001, to 6.66 in 2002. (See Table 11). 
The average number of DDDs per prescription items was the total number of DDDs 
for the whole year divided by the total number of prescription items for 
benzodiazepines each year. In 2001 the average number of DDDs per prescription 
items was 21.97 and it was 21.64 in 2002. On average therefore, each prescription 
item was for 22 days supply both 2001 and 2002.  
 
The number of DDDs per prescription items for each drug separately was about the 
same in 2001 and 2002 (See Table 12 and 13). All the typical hypnotics had average 
quantity of DDDs per prescription higher than the recommended, for 14 days supply. 
As an example, Flunitrazepam, which is classified as a Schedule 3 controlled drug, 
the average amount prescribed was equivalent to 33 days supply (average of 33 DDDs 
per prescription) while the figure for Nitrazepam was 36. The typical anxiolytics were 
also prescribed average from 13 days supply and greater as measured by the number 
of DDDs per prescription. On average each benzodiazepine patient had 7 
prescriptions for benzodiazepines or related drugs during the year 2001 and had on 
average 6 prescriptions for just benzodiazepine drugs. The lowest number of DDDs 
per prescription was seen for Clonazepam (antiepileptic indication) and Midazolam 
(premedication). The average total of DDDs per prescription item in 2002 for all 
included drugs was 22. For just benzodiazepines this figure was 21. When comparing 
the amount of DDDs per prescription item for each drug separately, the trend was the 
same as for 2001: the average number of DDDs per prescription was higher than the 
recommended guideline amount of 14 days supply. As an example, Flunitrazepam, 
which is classified as a Schedule 3 controlled drug, was on average prescribed for 33 
days supply (i.e. average no. of DDDs per prescription was 33) and for Nitrazepam 
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this figure was 36. The typical anxiolytics had average number of DDDs per 
prescription that ranged from 13 days supply and higher. The lowest average quantity 
of DDDs per prescription was seen for Clonazepam (antiepileptic indication) and 
Midazolam (premedication).  
 
Year 2001 
(n=20,114) 
International Non-
Proprietary Name 
(All dosage forms) 
ATC code Total No. of 
Prescription 
Items 
Number of 
DDDs 
Number of 
DDDs /Item 
Ave No. of 
Items 
/Benzo* 
Patient  
Diazepam N05BA01 20,607 440,854.10 21.39 1.025 
Chlordiazepoxide N05BA02 2,695 36,869.33 13.68 0.134 
Clorazepate N05BA05 1,772 32,355.75 18.26 0.088 
Lorazepam N05BA06 1,776 48,256.00 27.17 0.088 
Bromazepam N05BA08 9,649 121,845.30 12.63 0.480 
Clobazam N05BA09 1,358 40,191.50 29.60 0.068 
Prazepam N05BA11 783 11,326.33 14.47 0.039 
Alprazolam N05BA12 25,724 424,407.00 16.50 1.279 
Flurazepam N05CD01 11,045 258,155.00 23.37 0.549 
Nitrazepam N05CD02 5,492 199,400.00 36.31 0.273 
Flunitrazepam N05CD03 4,386 144,873.00 33.03 0.218 
Triazolam N05CD05 2,742 85,271.50 31.10 0.136 
Lormetazepam N05CD06 7,309 183,192.00 25.06 0.363 
Temazepam N05CD07 22,034 491,734.00 22.32 1.095 
Midazolam  N05CD08 187 1,729.33 9.25 0.009 
Zopiclone N05CF01 12,666 371,581.50 29.34 0.630 
Zolpidem N05CF02 7,886 173,985.00 22.06 0.392 
Zaleplon N05CF03 1,041 19,076.00 18.32 0.052 
Clonazepam N03AE01 1,605 8,018.06 5.00 0.080 
Total 140,757 3,093,120.71 21.97 6.998 
Total without N03AE01 139,152 3,085,103.00 22.17 6.918 
Total without N03AE01 and 
N05CF 
117,559 2,520,460.50 21.44 5.844 
*Benzo population includes all patients prescribed benzodiazepine and related drugs (ATC 
code: N05BA, N05CD, N05CF and N03AE01) in the NEHB GMS population. 
 
Table 12. Year 2001 (Jan-Dec) broken down by drug: Prescribing frequency of 
benzodiazepines and related drugs and the average number of DDDs dispensed per 
prescription item. 
 
 
 
 
 
 
Year 2002 
(n=21,513) 
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International Non-
Proprietary Name 
(All dosage forms) 
ATC code Total No. of 
Prescription 
Items 
Total No. of 
DDDs 
No. of 
DDDs/Item 
Ave. No. of 
Items/Benzo* 
Patients 
Diazepam N05BA01 22,697 464,777.90 20.48 1.055 
Chlordiazepoxide N05BA02 3,011 39,618.00 13.16 0.140 
Clorazepate N05BA05 1,831 34,620.00 18.91 0.085 
Lorazepam N05BA06 2,147 52,298.40 24.36 0.100 
Bromazepam N05BA08 10,451 130,422.45 12.48 0.486 
Clobazam N05BA09 1,300 38,223.50 29.40 0.060 
Prazepam N05BA11 836 11,985.33 14.34 0.039 
Alprazolam N05BA12 30,429 490,436.25 16.12 1.414 
Flurazepam N05CD01 12,062 275,763.00 22.86 0.561 
Nitrazepam N05CD02 5,853 211,966.00 36.21 0.272 
Flunitrazepam N05CD03 4,383 146,595.00 33.45 0.204 
Triazolam N05CD05 2,984 93,832.50 31.45 0.139 
Lormetazepam N05CD06 8,417 210,528.00 25.01 0.391 
Temazepam N05CD07 24,678 543,936.50 22.04 1.147 
Midazolam N05CD08 186 1,444.00 7.76 0.009 
Zopiclone N05CF01 15,696 462,212.00 29.45 0.730 
Zolpidem N05CF02 11,353 249,294.50 21.96 0.528 
Zaleplon N05CF03 1,015 17,637.00 17.38 0.047 
Clonazepam N03AE01 1,656 7,812.63 4.72 0.077 
Total 160,985 3483,402.96 21.64 7.484 
Total without N03AE01 159,329 3475,590.33 21.81 7.410 
Total without N03AE01 and 
N05CF 
131,265 2746,446.83 20.90 6.100 
*Benzo population includes all patients prescribed benzodiazepine and related drugs (ATC 
code: N05BA, N05CD, N05CF and N03AE01) in the NEHB GMS population. 
  
Table 13. Year 2002 broken down by drug: Prescribing frequency of benzodiazepines and 
related drugs and the average number of DDDs dispensed per prescription item. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Six-Month Data 
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1st 6-Month periods (Jan-Jun) for 2001-2003 
 
Jan-June Total 
No of 
Claims 
Total No. of 
Prescription 
Items 
Total No. of 
DDDs 
No. of 
DDDs 
/Item 
Ave. No. of 
Items /GMS 
Patient 
Ave. No. of 
Items 
/Benzodiazepi
ne patient* 
Ave. No. 
of 
Claims 
/Benzodi
azepine 
patient* 
2001 50,424 67,967 1,506,820.20 22.17 0.65 
 (67967/105247) 
4.83 
(67967/14081) 
3.58 
(50424/140
81) 
2002 69,958 78,745 1,711,049.37 21.73 0.75 
 (78745/104445) 
4.76 
(78745/16527) 
4.23  
(69958/165
27) 
2003 73,855 83,227 1,795,104.64 21.57 0.80  
(83227/103787) 
4.95 
(83227/16815) 
4.39 
(73855/168
15) 
Table 14. Six-Month (Jan-Jun) period data; prescribing frequency and average number of 
DDDs dispensed per prescription item for benzodiazepine and related drugs. 
 
During the first six months period 2001, 13.4% (14081/105247) of the total GMS 
population in the NEHB were prescribed a benzodiazepine derivate or related drug at 
least once. For the same period in 2002 and 2003 this figure had increased slightly to 
15.8% (16527/104445) and 16.2% (16815/103787) respectively - (for population data see 
Chart1).  
 
On average, each GMS patient received 0.65, 0.75 and 0.8 prescription items during 
jan-jun in  2001, 2002 and 2003 respectively. Taking only those GMS patients 
prescribed a benzodiazepine or related drug (benzodiazepine patient) into account, the 
average number of prescription items per patient was 4.83, 4.76 and 4.95 for each 
respective period. The average number of claims per benzodiazepine patient increased 
from 3.58 the first period of 2001, to 4.23 in 2002 and 4.39 in 2003. (See Table 14.)  
 
During the period the average number of DDDs per prescription items was 22, or 22 
days supply. The number of DDDs per prescription items for each drug separately for 
the period Jan-Jun 2003 was about the same as in 2001 and 2002. For details see 
Table 12, 13 and 15.  
 
 
1st six-month period: Jan-June 2003 
(n=16,815) 
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International-Non 
Proprietary Name 
(All dosage forms) 
ATC code Total No. of 
Prescription 
Items 
Total No. of 
DDDs 
Ave No. of 
DDDs /Item 
Ave. No. of 
Items 
/Benzodiazep
ine patient*  
Diazepam N05BA01 11,437 234,369.90 20.49 0.680 
Chlordiazepoxide N05BA02 1,533 20,450.50 13.34 0.091 
Clorazepate N05BA05 892 17,162.63 19.24 0.053 
Lorazepam N05BA06 1,138 27,537.00 24.20 0.068 
Bromazepam N05BA08 5,268 64,611.45 12.26 0.313 
Clobazam N05BA09 650 18,555.00 28.55 0.039 
Prazepam N05BA11 395 6,000.33 15.19 0.023 
Alprazolam N05BA12 15,438 248,092.25 16.07 0.918 
Flurazepam N05CD01 6,152 136,028.00 22.11 0.366 
Nitrazepam N05CD02 2,627 95,692.00 36.43 0.156 
Flunitrazepam N05CD03 2,137 69,836.00 32.68 0.127 
Triazolam N05CD05 1,474 46,281.50 31.40 0.088 
Lormetazepam N05CD06 4,090 102,618.50 25.09 0.243 
Temazepam N05CD07 12,206 269,687.50 22.09 0.726 
Midazolam N05CD08 81 515.33 6.36 0.005 
Zopiclone N05CF01 9,027 262,950.50 29.13 0.537 
Zolpidem N05CF02 7,261 162,238.00 22.34 0.432 
Zaleplon N05CF03 434 8,029.00 18.50 0.026 
Clonazepam N03AE01 987 4,449.25 4.51 0.059 
Total 83,227 1,795,104.64 21.57 4.950 
Total without N03AE01 82,240 1,790,655.39 21.77 4.891 
Total without N03AE01 and 
N05CF 
65,518 1,357,437.89 20.72 3.896 
Table 15. Six-Month (Jan-Jun) 2003 broken down by drug: Prescribing frequency of 
benzodiazepines and related drugs and the average number of DDDs dispensed per 
prescription item. 
 
 
2nd six-month period (Jul-Dec), 2001-2002 
Jul-Dec Total 
No. of 
Claims 
Total No. 
of 
Prescripti
on Items 
Total No. of 
DDDs 
No. of 
DDDs 
/Item 
Ave. No. of 
Items /GMS 
Patients 
Ave. No. of 
Items 
/Benzodiaze
pine 
patient* 
Ave. No. of 
Claims 
/Benzodiaze
pine 
patient* 
2001 65176 72790 1,586,300.51 21.79 0.69 
(72790/105247) 
4.51 
(72790/16149) 
4.04 
(65176/116149) 
2002 73213 82240 177,235,3.59 21.5 0.79 
(82240/104445) 
4.92 
(82240/16724) 
4.38 
(73213/16724) 
* 2003 Data (July-Dec) was not available for this period 
Table 16. Six-month (Jul-Dec) prescribing frequency of benzodiazepine and related drugs 
and average number of DDDs dispensed per prescription item. 
 
During the period Jul-Dec in 2001, 15.5% (16149/105247) of the total GMS population 
in the NEHB were prescribed a benzodiazepine derivative at least once. For the same 
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period in 2002 this figure had increased to 15.8% (16724/104445) - (for population data 
see Chart 1).  
 
On average, each GMS patient received 0.69 prescription items during Jul-Dec 2001 
and 0.79 for the same period in 2002. The average number of prescription items per 
benzodiazepine patient was 4.51 and 4.92 for the respective period. The average 
number of claims per benzodiazepine patient increased from 4.04 the second period in 
2001, to 4.38 in 2002. (See Table 16.)  
 
The average number of DDDs per prescription item was 22.79 in 2001 and 21.5 in 
2002. On average it is estimated that each prescription item was for 22 days supply in 
every period as for the whole year periods.  
 
 
5.5 Analysis of GMS Prescribed Quantities of Benzodiazepine and Related Drugs 
Yearly Data 
 
There was an increase in the overall prescribing of benzodiazepines and related drugs 
in 2002 compared to 2001. Both the hypnotics and anxiolytics were prescribed in 
greater quantities as measured by DDD/1000 GMS Patients/Day in 2002 than in 2001, 
though the increase was higher for the hypnotic drugs. The increase among the 
hypnotics was greater for the benzodiazepine-related hypnotics than for the 
benzodiazepines (See Table 17 and Chart 12, 13). 
  
 
 
 
 
 
 
 
 
 
    
 
No. of DDDs/1000 GMS Patients/Day 
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ATC Categories 2001 
(n=105,247) 
2002 
(n=104,445) 
Benzo & Related (N05BA, N05CD, 
N05CF and N03AE01) 
80.518 91.374 
Benzo & Related without N03AE01 80.310 91.169 
HYPNOTICS 
Benzodiazepine (N05CD) 35.517 38.928 
Benzodiazepine-related (N05CF) 14.699 19.126 
Total (N05CD & N05CF) 50.216 58.054 
ANXIOLYTICS 
Benzodiazepine (N05BA) 30.010 33.115 
Table 17. 2001-2002 GMS Prescribed Benzodiazepines & Related Drug DDDs by Category 
 
 
 
Prescribed Benzodiazepines & Related Drug Categories vs. DDDs by 
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Chart 12. 2001-2002 GMS Prescribed Benzodiazepines & Related Drug DDDs by Category 
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 Quantity of DDDs prescribed for Benzodiazepines & 
Related Drug by Drug Category per year
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Chart 13. 2001-2002 GMS Prescribed Benzodiazepines & Related Drug DDDs by Category 
 
 
 
Six-Month Data – 1st Six-Month Period 
 
The overall prescribing of benzodiazepines and related drugs gradually increased 
during the 1st six month period of 2002 and of 2003 compared to 2001. There was a 
slight increase in the amount of DDD/1000 GMS Patients/Day for the anxiolytics, 
while a greater increase was seen for the hypnotic drugs. Among the hypnotics both 
the benzodiazepines and the benzodiazepine-related drugs increased during Jan-Jun in 
2002 compared to 2001. But between 2002 and 2003 only the benzodiazepine-related 
drugs increased while the benzodiazepines marginally decreased. (See Table 18 and 
Chart 14,15). 
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No. of DDDs/1000 GMS Patients/Day 
 2001 (Jan-Jun) 
n=105247 
2002 (Jan-Jun) 
n=104445 
2003 (Jan-Jun) 
n=103787 
Total Benzo (N05BA, N05CD, 
N05CF, N03AE01) 
79.099 90.510 95.558 
Benzo without N03AE01 78.89 
 
90.283 95.321 
HYPNOTICS 
Total (N05CD and N05CF) 48.885 57.463 61.421 
Benzodiazepine (N05CD) 35.06 38.996 38.362 
Benzodiazepine-related 
(N05CF) 
13.825 18.467 23.06 
ANXIOLYTICS 
Benzodiazepine  (N05BA) 29.999 32.819 33.9 
Table 18. 1st six month period (Jan-Jun) of 2001-2003 GMS Prescribing of Benzodiazepines 
& Related Drug by DDDS by Category 
 
   
Prescribed Benzodiazepines & Related Drug Categories vs. DDDs by 
Year for 1st 6-Months (2001-2003)
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 Chart 14. 1st six month (Jan-Jun) period of 2001-2003, GMS Prescribed Benzodiazepines & 
Related Drug DDDS by Category 
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Chart 15. 1st six month (Jan-Jun) period of 2001-2003, GMS Prescribed Benzodiazepines & 
Related Drug DDDS by Category 
 
2nd Six-Month Period 
 
The overall prescribing of benzodiazepines and related drugs was higher in Jul-Dec 
2002 compared to the same period in 2001. The amount of DDDs/1000 GMS 
Patients/Day increased from 81.9 to 92.2 and both figures were higher than the data 
from the 1st six month period of 2001 and of 2002. There was a slight increase in the 
quantities prescribed for the anxiolytics, while a greater increase was seen for the 
hypnotic drugs. Among the hypnotics both the benzodiazepines and the 
benzodiazepine-related drugs increased during Jul-Dec in 2002 compared to 2001, 
though the increase was higher for the benzodiazepine-related hypnotics than for the 
benzodiazepines (See Table 19 and Chart 17, 18). 
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No. of DDDs/1000 GMS Patients/Day 
 2001 (Jul-Dec) 
n=105,247 
2002 (Jul-Dec) 
n=104,445 
Total Benzo (N05BA, N05CD, 
N05CF and N03AE01) 
81.914 92.224 
Benzo without N03AE01 81.706 92.039 
HYPNOTICS 
Total (N05CD and N05CF) 51.516 58.637 
Benzodiazepine (N05CD) 35.964 38.861 
Benzodiazepine-related 
(N05CF) 
15.552 19.776 
ANXIOLYTICS 
Benzodiazepine (N05BA) 30.188 33.403 
Table 19. 2nd Six-Months (Jul-Dec) 2001-2002 GMS Prescribed Benzodiazepines & Related 
Drug DDDS by Category. 
 Prescribed Benzodiazepines & Related Drug Categories vs. Total DDDs 
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Chart 17. 2nd Six-Months (Jul-Dec) 2001-2002 GMS Prescribed Benzodiazepines & Related 
Drug DDDS by Category 
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Chart 18. 2nd Six-Months (Jul-Dec) 2001-2002 GMS Prescribed Benzodiazepines & Related 
Drug DDDS by Category 
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5.6 Long-Term Use Analysis 
Yearly Data 2001: 
Of the 20114 benzodiazepine patients in the GMS population, NEHB, 7429 or 36.9% 
(7429/20114) had six or more prescription items for benzodiazepines or related drugs 
in either or both of the two six month periods. There were 3544 benzodiazepine 
patients, or 17.6% (3544/20114) who had six or more prescription items in just one of 
the six-month periods and 3885 patients, or 19.3% (3885/20114) who had six or more 
prescriptions in both of the six month periods (or in other words, had 12 or more 
prescriptions per year). (See Table 20).   
 
Yearly data 2002: 
During 2002, 8548 of the 21513 benzodiazepine patients, or 39.7% (8548/21513) had 
6 or more prescription items in either or both of the two six month periods. There 
were 3601 benzodiazepine patients, or 16.7% (3601/21513) who had six or more 
prescription items in just one of the six-month periods and 4947 patients, or 23.0% 
(4947/21513) who had six or more prescriptions in both of the six month periods (or 
in other words, had 12 or more prescriptions per year). The number of long-term users 
(based on prescription items) was higher in 2002 than 2001. (See Table 20).   
 
 
 
Long-term Use During Jan-Jun and Jul-Dec 
Based on No. of Prescription Items/6-Month Period* 
 2001 (n=20,114) 2002 (n=21,513) 
% of Patients Receiving≥ 6 Items 
in Either one  6-Month Periods 
17.6%(3544) 16.7% (3601) 
% of Patients Receiving ≥6 Items 
in Both 6-Month Periods 
19.3% (3885) 23.0% (4947) 
% of Patients Receiving ≥6 Items 
in Either or Both  6-Month 
Periods 
36.9% (7429) 39.7% (8548) 
*Items may not have been dispensed in consecutive months, and patients may have 
received more than one item per month. 
Table 20. Long-term Use During Jan-Jun and Jul-Dec based on No. of Prescription 
Items/6-Month Period 
 
It was only possible to look at long term dispensing in consecutive months for the 
whole year 2002. The data available for 2001 composed of two six month periods 
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(Jan-June) and (July-Dec) and was not broken down by month as the 2002 and there 
was no data available for the 2nd six month period in 2003 at the time for the study.   
 
Of the 21513 benzodiazepine patients in the GMS population, NEHB 10509 or 48.9% 
(10509/21513) had prescription items in three or more consecutive months. 
Accordingly 11004 or 51.1% of the patients did not prescription items in three or 
more consecutive months. 6522 patients, or 30.3% had prescription items in six or 
more consecutive months and 2097, or 9.7% had prescriptions in every month over 
the year 2002. (See Table 21).  
 
Of the whole GMS population, NEHB, 10.1% (10509/104445) had prescription items 
in three or more consecutive months, 6.4% had prescriptions in six or more 
consecutive months and 2.0% had prescriptions in every month during the year 2002 
(See Table 21).   
 
Long-term Dispensing in Consecutive Months  
Jan-Dec 2002 
Consecutive Dispensing Period % of Benzodiazepine patients 
(n=21,513) 
% of GMS Patients 
(n=104445) 
Prescription items in 
≥3-consecutive months  
48.9% (10509) 10.1% (10509) 
Prescription items in  
≥6-consecutive months 
30.3%  (6522) 6.2% (6522) 
Prescription items in  
all 12-months 
9.7%   (2097) 2.0%   (2097) 
Table 21. Long-term Dispensing in Consecutive Months during 2002 
 
Six-Month Data 
2001 
During Jan-Jun 38.6% (5442/14081) of the benzodiazepine patients had ≥ six 
prescription items. For the period Jul-Dec this figure was 36.4% (5872/16149). (See 
Table 22). 
2002 
For the period Jan-Jun 39.8% (6584/16527) of the benzodiazepine patients had six 
prescription items or more. For the second six month period the same figure was 
41.3% (6911/16724). (See Table 22).   
2003 
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In Jan-Jun there were 6966, or 41.4% (6966/16149) patients with six or more 
prescription items during this six month period. (See Table 22).  
 
Yearly long-term use within a 6-month period* 
 Patients with ≥6 prescription items in either or both 6-month period 
6-Month Period 2001 2002 2003 
Jan-Jun 38.6% (5442/14081) 39.8% (6584/16527) 41.4% (6966/16815) 
Jul-Dec 36.4% (5872/16149) 41.3% (6911/16724) N/A 
*Items may not have been dispensed in consecutive months, and patients may have received more than 
one item per month. There was no data available for the period Jul-Dec in 2003 at the time for the 
study. 
Table 22. Yearly long-term use within a 6-month period 
 
Long-term use, Consecutive 6-month period dispensing 2002: 
During Jan-Jun 48.1% (7943/16527) of the benzodiazepine patients had prescription 
items in three or more consecutive months. In the period  Jul-Dec this figure was 
50.6% (8459/16724).  21.1% (3484/16527) of patients had prescriptions in every 
month during the period Jan-Jun and this figure increased in Jul-Dec to 25.1% 
(4204/16724). (See table 23).   
 
Long-term use, Consecutive 6-month period dispensing 2003 
For the period Jan-Jun 51.8% (8703/16815) of the patients have prescription items in 
three or more consecutive month and 25.4% (4274/16815) have prescription items in 
every month. (See table 23).   
 
Long-term use: Consecutive 6-month period dispensing 
 2002 2003 
Prescription items in  
≥3 consecutive months 
  
Jan-Jun 48.1% (7943/16527) 51.8% (8703/16815) 
Jul-Dec 50.6% (8459/16724) N/A 
Prescription items in  
≥6 consecutive months 
  
Jan-Jun 21.1% (3484/16527) 25.4% (4274/16815) 
Jul-Dec 25.1% (4204/16724) N/A 
Table 23. Long-term use: Consecutive 6-month period dispensing 2002 and 2003. 
 
 
6. DISCUSSION 
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Since it became clear in the 1980´s that extended benzodiazepine use may lead to 
dependence and withdraw reactions, many studies have been performed to evaluate 
their use. However it is difficult to compare many of these studies because they differ 
in many respects. As for example in their definitions of: study population (sex, age, 
social class), benzodiazepine use (long-term, short-term/ever), study period (days, 
weeks, month, years), and the method used to collect the data (interviews, using 
prescription records) [25]. Because this study only includes the GMS population in 
the NEHB, most of the comparisons are made with the two studies that on request of 
the Benzodiazepine Committee examined the use of benzodiazepines in the GMS 
population, Ireland, and there by used the same type of study population and in 
addition used the same type of study method [4] and with an earlier national 
utilization study [26]. 
 
The use of benzodiazepines or related drugs in the adult GMS population NEHB, in 
terms of the quantity of DDDs/1000 GMS Adults/Day dispensed was 103.48 for the 
year 2001 and increased to 117.56 during 2002. The prescribed quantities for both the 
hypnotics and anxiolytics were higher in 2002 compared to 2001, though the 
proportional increase was greater for the hypnotic drugs. Among the hypnotics, the 
increase was greater for the benzodiazepine-related hypnotics than for the 
benzodiazepines (See Table 17 and Chart 12, 13). The overall prescribing of 
benzodiazepines and related drugs gradually increased during the 1st six month period 
of 2002 and 2003 compared to 2001. The total number of DDDs/1000 GMS 
Adults/Day for all the included drugs increased from 101.6 in the 2001 to 116.5 
respectively 123.0 for the same periods in 2002 and 2003.  
 
Some of the increase may have been a result of the extension of the GMS scheme to 
all of those ≥70 years of age. Two factors suggest that the influence of this policy was 
limited; firstly, a steady increase in total benzodiazepine utilization nationally was 
reported for 1995-2000 [17], and between 1977 and 1987 [26]; secondly, the patients 
who became eligible in 2001 can be considered to be affluent and these patients are 
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much less likely to receive benzodiazepines [28], a difference that has also been 
consistent over time [26]. 
 
The increased prescribing of long acting drugs was proportionally less than that of the 
intermediate-short acting agents resulting in a slight shift towards the prescribing of 
short acting benzodiazepines in both the anxiolytic and hypnotic sub-groups. 
However the most frequently prescribed of the long acting drugs maintained their 
utilization levels suggesting that there was little switching within each sub-group. The 
quantity of drugs prescribed per prescription fell by around 2-3% indicating a 
reduction in the duration of prescribing, but the number of items prescribed per 
patient rose, suggesting slightly smaller quantities prescribed more frequently. 
Increasing use of these drugs for indications other than anxiety and insomnia cannot 
be ruled out, however, the exclusion of those under 15 years of age and of the 
antiepileptic, clonazepam, and the parenteral sedative, midazolam, limited the number 
of confounding factors. 
 
The GMS population serves all of the elderly, a group whose pharmacodynamic 
responses and pharmacokinetic handling of benzodiazepines is known to differ from 
that of young adults [6,23] and long-acting drugs are more likely to produce effects on 
cognitive function and upon motor co-ordination with a variety of adverse 
consequences[13,18]. Prescribing guidelines for the elderly recommend that long-
acting benzodiazepines and high doses of short-intermediate acting drugs should not 
be used [6, 23, 29], but in this study, it was not possible to identify the elderly and so 
to examine the drugs and doses that were dispensed for them. Because the DDD is 
defined as an average recommended adult dose, this is often greater than the dose 
recommended for elderly patients BNF, so that at a given level of utilization, the 
exposure of the elderly to high doses is more likely. Taken together with the apparent 
stability of the utilization patterns for the long acting agents it is highly probable that 
some benzodiazepine prescribing for the elderly is sub-optimal as others have shown2. 
 
Of the whole GMS population, NEHB, 10.1% (10509/104445) received prescription 
items in 3 or more consecutive months, 6.4% received prescriptions in 6 or more 
consecutive months and 2.0% received prescriptions in every month during the year 
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2002. (See table 21). These findings are higher than the results from the Dutch study, 
described above, which  reported that 2% of the NHA population in 1997 used 
benzodiazepines for more than 6 months and 0.6% used benzodiazepines in every 
month during a one year observation [25]. However it is difficult to draw firm 
conclusions from the comparison of these results because of differences in the 
population and study method. 
 
As a rough estimation of the extended use of benzodiazepines and related drugs 
among the users, the average number of claims and prescription items were calculated 
(See Table 11, 14, 16). The average number of claims for benzodiazepines and related 
drugs increased from 3.6 in Jan-Jun 2001, to 4.2 in 2002 and to 4.4 in 2003 among the 
patients prescribed benzodiazepines in the GMS population of the NEHB. (See Table 
14.) This is similar as for GMS population, ERHA, who received approximately 4.3 
claims each for benzodiazepines during Jan-Jun 1999 and 2000 [4]. Although the 
ERHA study did not include the benzodiazepine-related drugs (with ATC code 
N05CF) which are included in this study. The average number of claims and 
prescription items for the whole year data in this study was 5.75 respectively 7 in 
2001 and 6.66 respectively 7.48 in 2002. These findings may indicate that many users 
take benzodiazepines on a continuing basis. 
 
As an effort to further evaluate the long-term use both the number of prescription 
items dispensed per six month period and prescription dispensing in consecutive 
months (See Table 20-23) were analysed. The results indicate that the prescribing of 
benzodiazepines and related drugs in this population were at a high level prescribed 
for long-term use which is against the advised guidelines (they should not be 
prescribed for more than 2-4 weeks [4, 6]). During 2002, 10509 benzodiazepine 
patients, or 48.9% had prescriptions in three or more consecutive months. Six 
thousand five hundred twenty two benzodiazepine patients or 30.3% received 
prescriptions in ≥ six consecutive months and 2097 or 9.7% were dispensed 
prescriptions in every month during 2002. 
 
In the 1980s GMS benzodiazepine utilisation was found to be 71.88 DDD/1000/day 
[26]. The population studied included those under15 years of age since it was not 
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possible to separate out patients in that age group who received prescriptions and it 
represents the total GMS population not just those receiving benzodiazepines. The 
composition of the anxiolytic benzodiazepine group (N05B) was slightly different 
since bromazepam and alprazolam had only recently been introduced. Among the 
hypnotic group flunitrazepam and lormetazepam were introduced in 1983 and 1982 
respectively while Zopiclone was introduced in 1989 and Zaleplon and Zolpidem 
were introduced in 1999. The rank order of the main drugs in each group at different 
times suggests that the national figures reflect some shift towards prescribing shorter-
acting sedative benzodiazepines and an increase in the prescribing of some of the 
non-benzodiazepine hypnotics [26]. While the increased use of short-term agents is 
welcome, there is still a high level of use of the longer acting drugs in the GMS 
population, many of whom are elderly and at greater risk of direct and indirect 
adverse effects associated with these drugs. However, the total prescribing measured 
in DDDs/1000/day has continued to rise from 1977 throughout the 1980s [26] and 
1990s and this report shows that a steady increase is till occurring. This implies that at 
least some prescribers are prescribing additional shorter acting anxiolytics and non-
benzodiazepine hypnotics rather than simply substituting for longer-acting anxiolytics 
and older benzodiazepine hypnotics.  
 
The Benzodiazepine Committee Report in 2002 concluded that the utilization of 
benzodiazepine hypnotics had declined, but since triazolam, one of the 
benzodiazepine hypnotics, was omitted from their analysis, this conclusion was 
incorrect. Adjusting their figures shows that triazolam utilization increased by around 
46% from 1995-2000 and that of the total benzodiazepine hypnotic sub-group 
increased by almost 11% [4]. In this study, growth in the prescribing of hypnotics 
increased considerably but non-benzodiazepine hypnotics increased to a greater 
extent than benzodiazepine drugs, a pattern that has also been noted nationally [4, 26]. 
The small increase in benzodiazepine utilization implies long term prescribing for a 
cohort of patients. Taken together with the two thirds increase in non-benzodiazepine 
hypnotic utilization and the increase in the number of claims for these drugs 
accompanied by a fall (1.25%) in the number of DDDs per item of zopiclone but an 
increase (1.5%) in the number of DDDs per item of zolpidem, this strongly suggests 
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an increase in the population of patients prescribed a non-benzodiazepine drug. 
Overall therefore, there has been an increase in the utilization of hypnotic drugs. 
 
The efficacy, value and safety of the non-benzodiazepine hypnotics compared to the 
benzodiazepine hypnotics continue to be debated [6, 11, 30-31]. Further analysis 
could provide information on the patterns of usage by patients and of prescribing by 
GPs and its costs, allow the monitoring of trends in areas of social disadvantage and 
in response to policy implementation affecting both the medical use and abuse of 
these drugs [32-33]. Such information is a pre-requisite for informed and coherent 
policy developments at all levels and was recommended by the Benzodiazepine 
Committee [4]. 
 
The prescribing and use of these drugs raise complex and contentious issues [3, 5, 21, 
33-35]. The views and experiences of prescribers and patients appear to be discordant 
[3,21,35] and consequently, if a GP or Community Pharmacist raises the issue of 
dependence and withdrawal with a patient, there is the risk that the patient will 
transfer to another practitioner to maintain their supply. Use and abuse of 
benzodiazepines and the ‘z’ drugs, is reported to be high in drug/substance abusing 
patients and the widespread availability of the drugs contributes to this [11, 35-36]. 
GPs and Community Pharmacists recognize the problems of the drugs in patients and 
drug/substance misusers but see few alternatives to prescribing or opportunities to 
help with discontinuation via counselling and support services [37]. GPs’ role as 
gatekeepers puts the onus on them to prescribe appropriately or to refer [4, 33], but 
Community Pharmacists have a ‘duty of care’ to the patients for whom they dispense, 
and contractual responsibilities to review a patient’s medications, to monitor for the 
abuse of medicines, to promote cost-effective prescribing and to reduce waste in 
prescribing [38]. Since both practitioners are independent contractors of health 
services to the State, these roles provide potential for conflict between them, and act 
as a barrier to collaborative practice. 
 
It is clear that additional policy measures are needed to tackle this problem. Both the 
public and members of the Primary Care Teams and Networks should be alerted to 
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the level of sub-optimal prescribing of these drugs. Increased regulation to reduce the 
utilization of benzodiazepines may result in other, less suitable drugs being prescribed 
or no drug at all being provided, and have more effect on ‘non-problematic’ rather 
than ‘problematic’ patients [2, 32] and may reduce the access of patients with 
substantial clinical need for the drugs [39]. A multilevel regulatory approach has been 
suggested [33], but to be effective, it will have to ensure multi-disciplinary, 
collaborative practice and to be complementary to, a public health educational effort 
with community and ‘expert’ patient initiatives to promote public engagement.  
 
This study has several limitations; no information about diagnosis is recorded in the 
database so it was not possible to differentiate the indications for which these drugs 
had been prescribed; although it was possible to separate out the use of 
benzodiazepines in those under 15 years of age, further details of age bands, and of 
gender were not available and hence the data could not be transformed into 
Standardised Prescribing Ratios as developed by Johnson and colleagues [27]; a 
sample of prescriptions would be required to calculate Prescribed Daily Doses to 
supplement the information about the dose and duration of treatment that has been 
inferred from DDDs per prescription; the study population used is not representative 
for the overall Irish population (eligible patients include the socially disadvantaged 
and persons ≥ 70 years old); only the dispensed amount of the included drugs were 
evaluated, and this may or may not indicate the actual consumption of the drugs by 
the patient; the data was not available for each month of each of the times periods 
studied and only Health Board-wide data rather than Community Care Area or 
District Electoral District (DED) data so that a Small Area analysis could not be 
carried out, and since Deprivation indices are based upon DEDs, the relationship with 
prescribing and deprivation could not be explored. 
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